Copyright
©2007 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2007; 13(48): 6575-6580
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6575
Published online Dec 28, 2007. doi: 10.3748/wjg.v13.i48.6575
Group | Dose (mg/kg) | CD3 (%) | CD4 (%) | CD8 (%) | CD4/CD8 |
NS control | 0 | 46.2 ± 4.5 | 28.5 ± 1.4 | 17.7 ± 2.16 | 1.6 ± 0.1 |
CTX control | 40 | 37.5 ± 2.4b | 21.5 ± 2.2b | 16.3 ± 1.6 | 1.3 ± 0.1b |
SFAP + CTX | 50 + 40 | 38.7 ± 2.2 | 22.2 ± 2.3 | 16.7 ± 2.0 | 1.3 ± 0.2 |
SFAP + CTX | 100 + 40 | 39.7 ± 3.1 | 24.2 ± 2.3 | 16.2 ± 1.5 | 1.5 ± 0.1c |
SFAP + CTX | 200 + 40 | 42.3 ± 2.5d | 26.7 ± 2.3d | 16.8 ± 1.5 | 1.6 ± 0.1d |
- Citation: Chen HS, Chen J, Cui DL, Zheng YY, Xu AH, Chen G, Jia LC. Effects of a Shuangling Fuzheng anticancer preparation on the proliferation of SGC-7901 cells and immune function in a cyclophosphamide-treated murine model. World J Gastroenterol 2007; 13(48): 6575-6580
- URL: https://www.wjgnet.com/1007-9327/full/v13/i48/6575.htm
- DOI: https://dx.doi.org/10.3748/wjg.v13.i48.6575